411
Participants
Start Date
July 7, 2021
Primary Completion Date
July 15, 2022
Study Completion Date
July 15, 2022
AZD8233
PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
Placebo
Placebo solution
Research Site, København NV
Research Site, Hvidovre
Research Site, Herlev
Research Site, Roskilde
Research Site, Debrecen
Research Site, Békéscsaba
Research Site, Svendborg
Research Site, Orosháza
Research Site, Herning
Research Site, Trebišov
Research Site, Aarhus N
Research Site, Balatonfüred
Research Site, Viborg
Research Site, New Windsor
Research Site, A Coruña
Research Site, Ferrol
Research Site, Santiago de Compostela
Research Site, Suffolk
Research Site, Greensboro
Research Site, Mt. Pleasant
Research Site, Jacksonville
Research Site, Pembroke Pines
Research Site, Inverness
Research Site, Huntsville
Research Site, Seville
Research Site, Seville
Research Site, Stow
Research Site, Cincinnati
Research Site, Cincinnati
Research Site, Indianapolis
Research Site, Zaragoza
Research Site, Fargo
Research Site, Meridian
Research Site, Canoga Park
Research Site, Lincoln
Research Site, Benešov
Research Site, Brandýs nad Labem
Research Site, Brno
Research Site, Jaroměř
Research Site, Liberec
Research Site, Louny
Research Site, Ostrava-Dubina
Research Site, Příbram
Research Site, Teplice
Research Site, Uherské Hradiště
Research Site, Amsterdam
Research Site, Doetinchem
Research Site, Ede
Research Site, Gouda
Research Site, Harderwijk
Research Site, Rotterdam
Research Site, Bydgoszcz
Research Site, Chrzanów
Research Site, Krakow
Research Site, Lodz
Research Site, Puławy
Research Site, Ruda Śląska
Research Site, Tychy
Research Site, Wierzchosławice
Research Site, Bratislava
Research Site, Brezno
Research Site, Lučenec
Research Site, Prešov
Research Site, Rožňava
Research Site, Svidník
Research Site, L'Hospitalet de Llobregat
Lead Sponsor
AstraZeneca
INDUSTRY